Nektar pads wallet with $90M manufacturing plant sale to Ampersand

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar Therapeutics is extending its cash runway with the sale of one of its two main facilities.